Fralin graduate student invents new cancer drug delivery vehicle

Fralin graduate student invents new cancer drug delivery vehicle

BLACKSBURG, Va., Jan. 28, 2013 – Sean Hemp of Raleigh, N.C., a Ph.D. student in chemistry in the College of Science, is helping to invent new therapies that target genetic disease and cancer.

Working with Timothy Long, professor of chemistry in the College of Science and part of the Virginia Tech Center for Drug Discovery, Hemp creates polymers to deliver nucleic acid -- the molecules that carry genetic information within DNA and RNA.

"Sean exemplifies a genuine inventor. He has an unbridled passion coupled with keen intellect and infectious curiosity," said Long.

Delivering foreign DNA and RNA to the body is difficult, but can serve several health benefits, especially in the case of genetic disease and cancer, according to Hemp. Effective uptake of nucleic acids allows for the delivery of genetic code that may correct malfunctioning DNA or eliminate mutating cells, such as cancer.

"The body's natural defense system quickly detects naked DNA or RNA and eliminates them," said Hemp.  "Polymers are an important part of delivering the nucleic acid and targeting only cancerous cells."

Collaborating with a local biotech company, Techulon, Hemp is developing a phosphonium-based polymer for the delivery of nucleic acid. Phosphonium groups are positively charged and the nucleic acids are negatively charged, so the two electrostatically bind to produce a nanoparticle. This process creates a capsule in which the nucleic acid is protected by the polymer. After this binding occurs, the nanoparticle remains positively charged, making it more likely for cellular uptake since the cellular wall is negative.

However, a major challenge in drug delivery is avoiding damage to healthy cells.

"Most cancer therapeutics are pretty indiscriminate. They harm all cells, not just cancer cells. That's why someone undergoing chemotherapy can lose their hair," said Hemp. "The addition of targeting groups to the nanoparticles enables the selective treatment of cancer cells over healthy cells."

The cancer's rapid growth makes its vulnerable. The rapidly growing cells need nutrients and the inclusion of these nutrients as part of the weaponized nanoparticle allows researchers like Hemp to target only cancerous cells.

In trial studies, Hemp's team has been able to show the phosphonium polymer successfully delivers nucleic acid in a test tube. Working with Techulon, he translates this knowledge into application by preparing that polymer for in-vivo use.

Hemp has co-authored two papers which support these findings in Biomacromolecules journal: "Phosphonium-Containing Diblock Copolymers for Enhanced Colloidal Stability and Efficient Nucleic Acid Delivery" and "Phosphonium-Containing Polyelectrolytes for Nonviral Gene Delivery."

"The hope is to create the polymer. Once the drug delivery vehicle is there, researchers can change the nucleic acid and specifically tailor it to the type of cancer they are treating," said Hemp.

"Sean will surely invent the future," Long said. "His discoveries in siRNA delivery with serum stable vectors offers the chance to understand cancer treatment using unprecedented phosphorous-containing molecular structure."

The Fralin Life Science Institute strategically invests in targeted research areas within the life sciences. Such investments include recruitment and set-up support for new faculty members, retention and recognition of established faculty members, seed funds for new research projects, equipment purchases, graduate student recruitment and support, undergraduate research support, and support for outreach activities. Research initiatives within the life sciences receiving the highest priority for support include vector-borne disease, infectious disease, plant sciences, ecology and organismal biology, obesity, and cancer biology. The Fralin Life Science Institute is also actively engaged in cooperative partnerships with colleges, departments, and other institutes that support the life science community.

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.